Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ovarian Neoplasms | 7 | 2022 | 589 | 1.200 |
Why?
|
Polycomb Repressive Complex 1 | 6 | 2018 | 34 | 1.170 |
Why?
|
Interleukin-10 | 3 | 2022 | 72 | 0.960 |
Why?
|
Transcription, Genetic | 2 | 2019 | 403 | 0.890 |
Why?
|
Monkeypox virus | 1 | 2024 | 1 | 0.880 |
Why?
|
Prostatic Neoplasms | 2 | 2015 | 277 | 0.750 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2017 | 167 | 0.700 |
Why?
|
Cystathionine beta-Synthase | 4 | 2023 | 31 | 0.660 |
Why?
|
MicroRNAs | 3 | 2022 | 301 | 0.660 |
Why?
|
DNA Damage | 2 | 2022 | 151 | 0.650 |
Why?
|
Neoplasm Proteins | 1 | 2019 | 123 | 0.610 |
Why?
|
Oxazepines | 3 | 2013 | 4 | 0.610 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2019 | 281 | 0.550 |
Why?
|
Promoter Regions, Genetic | 3 | 2016 | 343 | 0.540 |
Why?
|
Apoptosis | 6 | 2018 | 775 | 0.510 |
Why?
|
Cystadenocarcinoma, Serous | 1 | 2016 | 32 | 0.500 |
Why?
|
Interleukin-18 | 1 | 2015 | 17 | 0.490 |
Why?
|
Cell Line, Tumor | 14 | 2020 | 1319 | 0.480 |
Why?
|
Carcinosarcoma | 1 | 2015 | 22 | 0.480 |
Why?
|
Isoxazoles | 2 | 2014 | 8 | 0.480 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 2 | 2014 | 24 | 0.470 |
Why?
|
Antineoplastic Agents | 8 | 2018 | 679 | 0.470 |
Why?
|
Uterine Neoplasms | 1 | 2015 | 71 | 0.460 |
Why?
|
Transforming Growth Factor beta | 1 | 2015 | 79 | 0.460 |
Why?
|
Interleukin-12 | 1 | 2014 | 19 | 0.460 |
Why?
|
Genetic Variation | 1 | 2015 | 242 | 0.440 |
Why?
|
Cell Proliferation | 9 | 2020 | 806 | 0.430 |
Why?
|
Inflammation | 2 | 2015 | 636 | 0.420 |
Why?
|
Drug Design | 1 | 2013 | 63 | 0.410 |
Why?
|
Tobacco Use | 1 | 2014 | 99 | 0.410 |
Why?
|
Amino Acids | 1 | 2013 | 84 | 0.410 |
Why?
|
Biomarkers, Tumor | 1 | 2016 | 404 | 0.400 |
Why?
|
Humans | 31 | 2024 | 28094 | 0.400 |
Why?
|
Animals | 17 | 2024 | 10415 | 0.360 |
Why?
|
Mice, Nude | 7 | 2019 | 331 | 0.360 |
Why?
|
Receptors, Estrogen | 1 | 2011 | 43 | 0.360 |
Why?
|
Trans-Activators | 1 | 2011 | 118 | 0.340 |
Why?
|
Female | 20 | 2022 | 15153 | 0.340 |
Why?
|
Survival Rate | 3 | 2016 | 430 | 0.330 |
Why?
|
Cell Movement | 5 | 2019 | 373 | 0.310 |
Why?
|
Xenograft Model Antitumor Assays | 5 | 2018 | 269 | 0.300 |
Why?
|
Cation Transport Proteins | 2 | 2020 | 60 | 0.300 |
Why?
|
Metal Nanoparticles | 2 | 2022 | 130 | 0.290 |
Why?
|
Mice | 9 | 2023 | 4650 | 0.270 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2020 | 465 | 0.270 |
Why?
|
Proto-Oncogene Proteins | 2 | 2017 | 140 | 0.260 |
Why?
|
Endothelium, Vascular | 2 | 2020 | 325 | 0.240 |
Why?
|
Mitochondria | 2 | 2020 | 369 | 0.240 |
Why?
|
Tumor Cells, Cultured | 2 | 2016 | 315 | 0.240 |
Why?
|
Epithelial-Mesenchymal Transition | 2 | 2016 | 115 | 0.240 |
Why?
|
Signal Transduction | 6 | 2020 | 1435 | 0.230 |
Why?
|
Hydrogen Sulfide | 3 | 2023 | 32 | 0.220 |
Why?
|
Breast Neoplasms | 5 | 2013 | 459 | 0.220 |
Why?
|
Host-Pathogen Interactions | 1 | 2024 | 91 | 0.210 |
Why?
|
Astrocytes | 1 | 2023 | 77 | 0.200 |
Why?
|
Rad51 Recombinase | 1 | 2022 | 10 | 0.200 |
Why?
|
Phosphorylation | 3 | 2019 | 578 | 0.200 |
Why?
|
Histones | 2 | 2019 | 93 | 0.190 |
Why?
|
Risk Factors | 2 | 2019 | 2081 | 0.190 |
Why?
|
Polymorphism, Restriction Fragment Length | 2 | 2013 | 26 | 0.190 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2013 | 21 | 0.180 |
Why?
|
Protein Kinases | 1 | 2022 | 152 | 0.180 |
Why?
|
Tuberculosis | 2 | 2013 | 25 | 0.180 |
Why?
|
Mitochondrial Membrane Transport Proteins | 2 | 2020 | 23 | 0.180 |
Why?
|
Mycobacterium tuberculosis | 2 | 2013 | 31 | 0.180 |
Why?
|
Calcium-Binding Proteins | 2 | 2020 | 62 | 0.180 |
Why?
|
Glycolysis | 2 | 2020 | 85 | 0.170 |
Why?
|
Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2020 | 6 | 0.170 |
Why?
|
Aged | 5 | 2023 | 5400 | 0.170 |
Why?
|
Mitochondrial Dynamics | 1 | 2020 | 12 | 0.170 |
Why?
|
Histone Deacetylase 1 | 1 | 2019 | 10 | 0.170 |
Why?
|
Histone Deacetylase 2 | 1 | 2019 | 10 | 0.170 |
Why?
|
Gold | 2 | 2022 | 130 | 0.170 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2020 | 60 | 0.160 |
Why?
|
Cytokines | 1 | 2022 | 447 | 0.160 |
Why?
|
Apelin Receptors | 1 | 2019 | 11 | 0.160 |
Why?
|
Neoplasm Metastasis | 1 | 2019 | 162 | 0.150 |
Why?
|
Brain | 1 | 2023 | 741 | 0.140 |
Why?
|
Pyrazines | 1 | 2017 | 24 | 0.140 |
Why?
|
Benzimidazoles | 1 | 2017 | 32 | 0.140 |
Why?
|
MCF-7 Cells | 2 | 2014 | 34 | 0.140 |
Why?
|
Middle Aged | 4 | 2018 | 7137 | 0.130 |
Why?
|
Endometrial Neoplasms | 1 | 2018 | 189 | 0.130 |
Why?
|
Histone Acetyltransferases | 1 | 2016 | 15 | 0.130 |
Why?
|
Drug Resistance, Multiple | 1 | 2016 | 20 | 0.130 |
Why?
|
India | 2 | 2014 | 142 | 0.130 |
Why?
|
Cell Differentiation | 2 | 2016 | 407 | 0.130 |
Why?
|
Aging | 1 | 2023 | 968 | 0.130 |
Why?
|
Adult | 4 | 2018 | 7739 | 0.130 |
Why?
|
Chaperonin 60 | 2 | 2013 | 2 | 0.120 |
Why?
|
Homeostasis | 1 | 2016 | 118 | 0.120 |
Why?
|
Oxidative Stress | 1 | 2020 | 668 | 0.120 |
Why?
|
Polymerase Chain Reaction | 3 | 2013 | 269 | 0.120 |
Why?
|
Rats | 4 | 2011 | 1576 | 0.120 |
Why?
|
Luciferases | 2 | 2014 | 49 | 0.120 |
Why?
|
Gene Frequency | 1 | 2015 | 185 | 0.120 |
Why?
|
Tumor Microenvironment | 1 | 2016 | 177 | 0.120 |
Why?
|
Genes, Reporter | 2 | 2014 | 87 | 0.120 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2016 | 138 | 0.120 |
Why?
|
Alleles | 1 | 2015 | 350 | 0.110 |
Why?
|
Doxorubicin | 2 | 2016 | 77 | 0.110 |
Why?
|
Transfection | 1 | 2015 | 318 | 0.110 |
Why?
|
Age Distribution | 1 | 2014 | 73 | 0.110 |
Why?
|
Sex Distribution | 1 | 2014 | 78 | 0.110 |
Why?
|
Cell Line | 2 | 2019 | 696 | 0.110 |
Why?
|
Genotype | 1 | 2015 | 456 | 0.110 |
Why?
|
Aged, 80 and over | 2 | 2018 | 2021 | 0.110 |
Why?
|
G1 Phase Cell Cycle Checkpoints | 1 | 2013 | 6 | 0.110 |
Why?
|
Prognosis | 1 | 2016 | 802 | 0.110 |
Why?
|
Comorbidity | 1 | 2014 | 258 | 0.110 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2014 | 77 | 0.110 |
Why?
|
Binding Sites | 2 | 2011 | 353 | 0.110 |
Why?
|
Nontuberculous Mycobacteria | 1 | 2013 | 2 | 0.100 |
Why?
|
RNA, Messenger | 1 | 2015 | 659 | 0.100 |
Why?
|
Mycobacterium Infections, Nontuberculous | 1 | 2013 | 6 | 0.100 |
Why?
|
Prevalence | 1 | 2014 | 497 | 0.100 |
Why?
|
Follow-Up Studies | 1 | 2015 | 1013 | 0.100 |
Why?
|
Mice, Knockout | 2 | 2016 | 848 | 0.100 |
Why?
|
Male | 5 | 2015 | 13489 | 0.100 |
Why?
|
Bacterial Proteins | 2 | 2013 | 485 | 0.090 |
Why?
|
Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2011 | 16 | 0.090 |
Why?
|
Pterocarpans | 1 | 2011 | 1 | 0.090 |
Why?
|
Estrogen Receptor beta | 1 | 2011 | 14 | 0.090 |
Why?
|
Osteoblasts | 1 | 2011 | 36 | 0.090 |
Why?
|
Tyrosine | 1 | 2011 | 92 | 0.090 |
Why?
|
Estrogens | 1 | 2011 | 56 | 0.090 |
Why?
|
Biomarkers | 1 | 2014 | 765 | 0.090 |
Why?
|
Receptor, IGF Type 1 | 1 | 2011 | 41 | 0.090 |
Why?
|
Thermodynamics | 1 | 2011 | 93 | 0.090 |
Why?
|
Cell Survival | 3 | 2018 | 409 | 0.090 |
Why?
|
Sulfonamides | 1 | 2011 | 73 | 0.090 |
Why?
|
Bone and Bones | 1 | 2011 | 75 | 0.090 |
Why?
|
Polypropylenes | 1 | 2010 | 6 | 0.090 |
Why?
|
Pancreatic Neoplasms | 1 | 2016 | 540 | 0.080 |
Why?
|
Dendrimers | 1 | 2010 | 15 | 0.080 |
Why?
|
Folic Acid | 1 | 2010 | 32 | 0.080 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2010 | 32 | 0.080 |
Why?
|
Bacteriological Techniques | 1 | 2010 | 18 | 0.080 |
Why?
|
Pyrones | 1 | 2009 | 6 | 0.080 |
Why?
|
Nanostructures | 1 | 2010 | 64 | 0.080 |
Why?
|
Mycoplasma pneumoniae | 1 | 2009 | 11 | 0.080 |
Why?
|
Pneumonia, Mycoplasma | 1 | 2009 | 9 | 0.080 |
Why?
|
Drug Carriers | 1 | 2010 | 115 | 0.080 |
Why?
|
Receptors, Calcium-Sensing | 1 | 2008 | 1 | 0.080 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 65 | 0.070 |
Why?
|
Antibodies, Bacterial | 1 | 2009 | 103 | 0.070 |
Why?
|
Liver | 1 | 2011 | 440 | 0.070 |
Why?
|
DNA, Mitochondrial | 1 | 2008 | 82 | 0.070 |
Why?
|
Transcription Factors | 1 | 2011 | 520 | 0.070 |
Why?
|
Muscle, Skeletal | 1 | 2011 | 634 | 0.060 |
Why?
|
Insulin | 2 | 2022 | 315 | 0.060 |
Why?
|
Cisplatin | 2 | 2017 | 179 | 0.060 |
Why?
|
Cells, Cultured | 2 | 2020 | 985 | 0.060 |
Why?
|
Protein Binding | 2 | 2017 | 658 | 0.060 |
Why?
|
Cystathionine | 1 | 2023 | 6 | 0.050 |
Why?
|
Checkpoint Kinase 1 | 1 | 2022 | 9 | 0.050 |
Why?
|
Recombinational DNA Repair | 1 | 2022 | 7 | 0.050 |
Why?
|
PTEN Phosphohydrolase | 1 | 2022 | 29 | 0.050 |
Why?
|
Opium | 1 | 2022 | 2 | 0.050 |
Why?
|
Tissue Distribution | 1 | 2022 | 137 | 0.050 |
Why?
|
DNA Repair | 1 | 2022 | 82 | 0.050 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2022 | 82 | 0.050 |
Why?
|
Leukocytes, Mononuclear | 1 | 2022 | 82 | 0.050 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2022 | 247 | 0.040 |
Why?
|
Interleukin-6 | 1 | 2022 | 193 | 0.040 |
Why?
|
Endoplasmic Reticulum | 1 | 2020 | 80 | 0.040 |
Why?
|
Sensitivity and Specificity | 2 | 2013 | 521 | 0.040 |
Why?
|
Sputum | 2 | 2010 | 8 | 0.040 |
Why?
|
Neoplasms | 1 | 2008 | 808 | 0.040 |
Why?
|
Hypoxia | 1 | 2020 | 89 | 0.040 |
Why?
|
Zebrafish | 1 | 2020 | 96 | 0.040 |
Why?
|
Nitrobenzoates | 1 | 2019 | 7 | 0.040 |
Why?
|
Pyrans | 1 | 2019 | 8 | 0.040 |
Why?
|
Rats, Sprague-Dawley | 2 | 2011 | 551 | 0.040 |
Why?
|
Disease Models, Animal | 2 | 2018 | 1459 | 0.040 |
Why?
|
Cell Adhesion | 1 | 2019 | 138 | 0.040 |
Why?
|
Models, Molecular | 2 | 2011 | 452 | 0.040 |
Why?
|
STAT3 Transcription Factor | 1 | 2019 | 97 | 0.040 |
Why?
|
Caspases | 1 | 2018 | 43 | 0.040 |
Why?
|
MAP Kinase Signaling System | 1 | 2019 | 95 | 0.040 |
Why?
|
Neoplasm Grading | 1 | 2018 | 104 | 0.040 |
Why?
|
Extracellular Matrix | 1 | 2019 | 117 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2019 | 155 | 0.040 |
Why?
|
Pyruvate Dehydrogenase Complex | 1 | 2017 | 19 | 0.030 |
Why?
|
Oxidative Phosphorylation | 1 | 2017 | 29 | 0.030 |
Why?
|
Mitogen-Activated Protein Kinase 7 | 1 | 2017 | 5 | 0.030 |
Why?
|
Microarray Analysis | 1 | 2017 | 64 | 0.030 |
Why?
|
Immunohistochemistry | 1 | 2018 | 463 | 0.030 |
Why?
|
Casein Kinase II | 1 | 2017 | 17 | 0.030 |
Why?
|
Disease Progression | 1 | 2019 | 473 | 0.030 |
Why?
|
Neoplasm Staging | 1 | 2018 | 478 | 0.030 |
Why?
|
Pancreatic Stellate Cells | 1 | 2016 | 6 | 0.030 |
Why?
|
Proteolysis | 1 | 2017 | 58 | 0.030 |
Why?
|
Lysine Acetyltransferase 5 | 1 | 2016 | 4 | 0.030 |
Why?
|
Acetylation | 1 | 2016 | 37 | 0.030 |
Why?
|
Calcium | 1 | 2017 | 235 | 0.030 |
Why?
|
Neuropilins | 1 | 2015 | 4 | 0.030 |
Why?
|
Second Messenger Systems | 1 | 2015 | 13 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2015 | 56 | 0.030 |
Why?
|
Glutathione | 1 | 2015 | 76 | 0.030 |
Why?
|
Paclitaxel | 1 | 2016 | 190 | 0.030 |
Why?
|
Neoplastic Stem Cells | 1 | 2016 | 141 | 0.030 |
Why?
|
Human Umbilical Vein Endothelial Cells | 1 | 2015 | 65 | 0.030 |
Why?
|
Phenotype | 1 | 2017 | 680 | 0.030 |
Why?
|
Epithelial Cells | 1 | 2016 | 248 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2015 | 179 | 0.030 |
Why?
|
Phosphoinositide Phospholipase C | 1 | 2014 | 5 | 0.030 |
Why?
|
Heterotrimeric GTP-Binding Proteins | 1 | 2014 | 6 | 0.030 |
Why?
|
Calcineurin | 1 | 2014 | 7 | 0.030 |
Why?
|
NFATC Transcription Factors | 1 | 2014 | 14 | 0.030 |
Why?
|
Active Transport, Cell Nucleus | 1 | 2014 | 17 | 0.030 |
Why?
|
Inhibitory Concentration 50 | 1 | 2014 | 34 | 0.030 |
Why?
|
Hep G2 Cells | 1 | 2014 | 31 | 0.030 |
Why?
|
Transcriptional Activation | 1 | 2014 | 86 | 0.030 |
Why?
|
Cyclic AMP | 1 | 2014 | 87 | 0.030 |
Why?
|
Calcium Signaling | 1 | 2014 | 72 | 0.030 |
Why?
|
HEK293 Cells | 1 | 2014 | 187 | 0.030 |
Why?
|
Mutation | 1 | 2017 | 845 | 0.030 |
Why?
|
Cost-Benefit Analysis | 1 | 2013 | 112 | 0.020 |
Why?
|
Caspase 8 | 1 | 2011 | 10 | 0.020 |
Why?
|
Membrane Potential, Mitochondrial | 1 | 2011 | 25 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 2011 | 60 | 0.020 |
Why?
|
Sesquiterpenes | 1 | 2011 | 22 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2011 | 90 | 0.020 |
Why?
|
Biological Availability | 1 | 2011 | 44 | 0.020 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 45 | 0.020 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2011 | 103 | 0.020 |
Why?
|
Uterus | 1 | 2011 | 31 | 0.020 |
Why?
|
Estrogen Receptor alpha | 1 | 2011 | 27 | 0.020 |
Why?
|
Skull | 1 | 2011 | 40 | 0.020 |
Why?
|
Bone Morphogenetic Protein 2 | 1 | 2011 | 29 | 0.020 |
Why?
|
Osteogenesis | 1 | 2011 | 41 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2011 | 267 | 0.020 |
Why?
|
Drug Stability | 1 | 2010 | 23 | 0.020 |
Why?
|
Technology, Pharmaceutical | 1 | 2010 | 9 | 0.020 |
Why?
|
Chemistry, Pharmaceutical | 1 | 2010 | 27 | 0.020 |
Why?
|
Microscopy, Electron | 1 | 2010 | 94 | 0.020 |
Why?
|
Spectrophotometry, Infrared | 1 | 2010 | 25 | 0.020 |
Why?
|
Solubility | 1 | 2010 | 73 | 0.020 |
Why?
|
Drug Compounding | 1 | 2010 | 30 | 0.020 |
Why?
|
Hemolysis | 1 | 2010 | 50 | 0.020 |
Why?
|
Spectrometry, Mass, Electrospray Ionization | 1 | 2010 | 71 | 0.020 |
Why?
|
Lithium Compounds | 1 | 2009 | 1 | 0.020 |
Why?
|
Resting Phase, Cell Cycle | 1 | 2009 | 2 | 0.020 |
Why?
|
Cyclization | 1 | 2009 | 2 | 0.020 |
Why?
|
Aluminum Compounds | 1 | 2009 | 3 | 0.020 |
Why?
|
G1 Phase | 1 | 2009 | 17 | 0.020 |
Why?
|
Surface Properties | 1 | 2010 | 134 | 0.020 |
Why?
|
Biological Transport | 1 | 2010 | 122 | 0.020 |
Why?
|
Tamoxifen | 1 | 2009 | 33 | 0.020 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2010 | 267 | 0.020 |
Why?
|
Pyrrolidines | 1 | 2009 | 11 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2010 | 180 | 0.020 |
Why?
|
Convalescence | 1 | 2009 | 6 | 0.020 |
Why?
|
Immunoglobulin M | 1 | 2009 | 28 | 0.020 |
Why?
|
Structure-Activity Relationship | 1 | 2009 | 208 | 0.020 |
Why?
|
Pharynx | 1 | 2009 | 14 | 0.020 |
Why?
|
Immunoglobulin A | 1 | 2009 | 23 | 0.020 |
Why?
|
Kinetics | 1 | 2010 | 545 | 0.020 |
Why?
|
Hypercalcemia | 1 | 2008 | 13 | 0.020 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2011 | 301 | 0.020 |
Why?
|
Acute Disease | 1 | 2009 | 155 | 0.020 |
Why?
|
Time Factors | 1 | 2013 | 1591 | 0.020 |
Why?
|
Piperidines | 1 | 2009 | 48 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2010 | 607 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 257 | 0.020 |
Why?
|
Molecular Structure | 1 | 2009 | 243 | 0.020 |
Why?
|
RNA, Transfer, Lys | 1 | 2008 | 1 | 0.020 |
Why?
|
Nepal | 1 | 2008 | 8 | 0.020 |
Why?
|
INDEL Mutation | 1 | 2008 | 7 | 0.020 |
Why?
|
Asia, Southeastern | 1 | 2008 | 11 | 0.020 |
Why?
|
Gene Flow | 1 | 2008 | 11 | 0.020 |
Why?
|
Herpesvirus 1, Human | 1 | 2008 | 24 | 0.020 |
Why?
|
Sequence Deletion | 1 | 2008 | 66 | 0.020 |
Why?
|
Genetics, Population | 1 | 2008 | 73 | 0.020 |
Why?
|
Antigens, Bacterial | 1 | 2009 | 161 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2009 | 270 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2010 | 769 | 0.020 |
Why?
|
Haplotypes | 1 | 2008 | 283 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2009 | 722 | 0.020 |
Why?
|
Base Sequence | 1 | 2008 | 584 | 0.020 |
Why?
|
Mothers | 1 | 2008 | 122 | 0.020 |
Why?
|
Models, Biological | 1 | 2008 | 466 | 0.020 |
Why?
|
Phylogeny | 1 | 2008 | 479 | 0.020 |
Why?
|
Young Adult | 1 | 2013 | 2732 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2008 | 547 | 0.020 |
Why?
|
Adolescent | 1 | 2013 | 3121 | 0.010 |
Why?
|